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Abstract
Background: Chronic obstructive pulmonary disease (COPD) is a progressive chronic disease characterized by
airflow obstruction that leads to shortness of breath and substantial negative impacts on health-related quality of
life (HRQL). The course of COPD includes periodic acute exacerbations that require changes in treatment and/or
hospitalizations. This study was designed to examine the responsiveness of Patient-Reported Outcomes
Measurement Information System® (PROMIS®) measures to changes associated with COPD exacerbation recovery.
Methods: A longitudinal analysis using mixed-effects models was conducted of people who were enrolled while
stable (n = 100) and those who experienced an acute exacerbation (n = 85). PROMIS (physical function, pain
interference, pain behavior, fatigue, anxiety, depression, anger, social roles, discretionary social activities, Global
Health, dyspnea severity and dyspnea functional limitations) and COPD-targeted HRQL measures were completed
at baseline and at 12 weeks.
Results: We administered PROMIS measures using computer adaptive testing (CAT), followed by administration of
any remaining short form (SF) items that had not yet been administered by CAT. Examination of the difference
between group differences from baseline to 12 weeks in the stable and exacerbation groups revealed that the
exacerbation group changed (improved) significantly more than the stable group in anxiety (p < .001 to p < .01; f2
effect size [ES] = 0.023/0.021), fatigue (p < .0001; ES = 0.036/0.047) and social roles (p < .001 to p < .05; ES = 0.035/
0.024). All effect sizes were small in magnitude and smaller than hypothesized. Depression was also statistically
significant (p < .05, SF only) but the ES was trivial. For all other PROMIS domains, the differences were not significant
and ES were trivial.
Conclusions: This longitudinal study provides some support for the validity of the PROMIS fatigue, anxiety, and
social roles domains in COPD, but further evaluation of responsiveness is warranted.
Keywords: Chronic obstructive pulmonary disease, COPD, Patient-reported outcomes, PROMIS
Background
Chronic obstructive pulmonary disease (COPD) is a het-
erogeneous group of slowly progressive diseases charac-
terized by airflow obstruction that interferes with
normal breathing and leads to shortness of breath or
dyspnea that can limit physical activity [1]. COPD is the
third leading cause of death in the U.S. and the only
leading cause of death increasing in prevalence [2, 3].
Those with COPD experience limitations in functioning
and well-being or health-related quality of life (HRQL)
comparable to or worse than patients with advanced
lung cancer [4].
COPD leads to progressive decline in lung function as-
sociated with worsening of symptoms. Many patients ex-
perience periodic exacerbations, defined as an acute
sustained worsening of their COPD, that result in un-
scheduled clinic or emergency department (ED) visits
and require antibiotics and/or steroids, with severe cases
requiring hospitalization for observation and treatment.
The decline in lung function, symptoms, and physical
function associated with exacerbations represent
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substantial negative impacts on HRQL and contribute to
the downward trajectory of disease over time [5, 6].
Measures of lung function, such as forced expiratory
volume in 1 s (FEV1) and forced vital capacity (FVC), are
used to estimate the severity of airflow limitation but fail
to capture the systemic manifestations and patient-
experienced impact of the disease [7, 8]. Hence, patient-
reported outcomes (PROs) are needed in COPD obser-
vational studies, clinical trials, and patient care [9].
Stable COPD is associated with relatively poor status in
several PRO domains, namely depression [10, 11], anx-
iety [11], fatigue [12–15], mobility, activities of daily liv-
ing (ADLs) [13] and social activities [13]. Acute
exacerbations of COPD are, by definition, characterized
by worsening of respiratory symptoms, including dys-
pnea [16–19] as well as decreased health-related quality
of life [20–22], lower levels of physical function [5, 20,
23, 24]; increased fatigue [23–26], depression and anx-
iety [23, 27–31], reduced social functioning [23, 28], and
to a lesser degree, increased pain [23] and anger [23].
Thus, COPD is a potentially informative target condition
for evaluating the measurement properties of PROs, in-
cluding change in outcomes that are expected to change
with recovery from an exacerbation (e.g., fatigue, anxiety,
mobility, ADLs, social activities) and stability in out-
comes that are expected to remain relatively unchanged
(e.g., depression).
The Patient Reported Outcomes Measurement Infor-
mation System® (PROMIS®) quantifies self-reported
health with domains relevant to multiple chronic dis-
eases and conditions, permitting selective or comprehen-
sive outcome assessment based on user interests and
needs. Each measure comprising this system was devel-
oped using standardized, rigorous psychometric methods
[32, 33] with testing in the general population and across
a number of different patient subgroups [34–39]. Most
PROMIS measures are universal (i.e., not disease-
specific), but some are particularly relevant to patients
with COPD such as fatigue, physical function, anxiety,
depression, dyspnea and social function. Although other
instruments exist to measure some or all of these out-
comes in various combinations [7, 40], PROMIS offers
single-site open access (www.healthmeasures.net) to
each measure, computer adaptive test (CAT) versions
for efficient assessments, and information on normative
values. Cross-sectional analyses in patients with COPD
provide support for the reliability and validity of PRO-
MIS measures [41].
Acute exacerbations of COPD are clinically relevant
events with important therapeutic and prognostic impli-
cations and with considerable heterogeneity in terms of
their clinical presentation [42]. The majority of the lit-
erature on impacts of acute exacerbations of COPD has
focused on respiratory symptoms, morbidity, mortality,
hospitalizations and disease-specific health-related qual-
ity of life questionnaires (e.g., St. George’s Respiratory
Questionnaire [43]) [44–51]. In contrast, this study ex-
amines the responsiveness of PROMIS measures of spe-
cific physical, mental and social health status domains
over 12 weeks in patients with COPD who were recover-
ing from an acute COPD exacerbation. We also studied
patients with COPD who were enrolled in a stable (non-
exacerbating) state and followed for 12 weeks to allow us
to explore any changes in the measures that were unre-
lated to exacerbation recovery. We hypothesized that
there would be significant improvement in most of the
PROMIS domain measures in COPD patients during re-
covery from exacerbation to a stable period, and that the
largest magnitude changes would be in physical func-
tion, fatigue, anxiety, dyspnea and social function. While
those in the stable condition might change over time
due to unmeasured factors, we hypothesized that there
would be little to no change over 12 weeks, and any ob-
served change would be smaller than that of patients re-
covering from an acute exacerbation.
Methods
This study used a longitudinal, multisite prospective co-
hort of two groups: 1) patients with COPD enrolled at
the time of an exacerbation, and 2) patients with COPD
enrolled at a time of stability. Both groups were followed
for 12 weeks and completed assessments at enrollment
(baseline) and then weekly for the remaining 11 weeks.
In this paper, we report on the baseline and 12-week
findings. Subjects were recruited from outpatient clinics
and hospitals at four research sites (University of North
Carolina Health System, NorthShore University Health-
System, Pittsburgh VA Medical Center, and Durham VA
Medical Center).
Participants
We enrolled patients 40 years and older with an estab-
lished clinical history of COPD in accordance with the
GOLD definition at the time of the study [52] and at
least a 10 pack/year history of smoking. Participants had
to be able to read and speak English and be able to see
and interact with a computer screen, mouse, and key-
board. People were excluded if, based on the input of
clinic staff or evidence in the medical chart, they had a
concurrent medical or psychiatric condition that pre-
cluded participation in the study or completion of self-
report questionnaires (e.g., dementia, uncontrolled
schizophrenia). They were also excluded if they had a
history of asthma without co-existent COPD or were ex-
periencing a heart failure exacerbation. For those en-
rolled into the exacerbation group, participants recruited
in the outpatient setting may have started treatment no
more than 3 days prior to the day of enrollment, and for
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participants recruited in the inpatient setting, no
more than 6 days prior to the day of enrollment.
Those enrolled into the stable state group had to be
exacerbation-free for a minimum of 2 months prior
to enrollment. An exacerbation was defined as sus-
tained worsening of COPD symptoms from stable
state and beyond normal day-to-day variations that is
acute in onset and necessitates a change in regular
medication in a patient with underlying COPD; in
addition, the exacerbation had to be established by a
clinic visit or hospitalization with a medical diagnosis
of COPD exacerbation and treatment with antibiotics
or corticosteroids [53].
The study was conducted in accordance with the
amended Declaration of Helsinki and was approved by
the Institutional Review Board (IRB) at each site (Uni-
versity of North Carolina, 08–0138; NorthShore Univer-
sity HealthSystem, EH04–179; Pittsburgh VA Medical
Center, 02683; Duke University, Pro00006904). At the
time of enrollment and prior to beginning the baseline
assessment, informed consent was obtained from all par-
ticipants included in the study.
Procedures
For those stable at enrollment, the baseline assess-
ment included questionnaire measures, pulmonary
function testing with GOLD classification [54], and a
six-minute walk test. Because of the compromised
health of those in an exacerbation state at enrollment,
only the questionnaires were administered; the six-
minute walk test (6MWT) and pulmonary function
testing with GOLD classification were performed at
the 12-week follow-up when patients had returned to
stable state. Thus, all analysis of clinical measures
(i.e., pulmonary function testing, GOLD classification,
6MWT) reflected data obtained when patients were
deemed stable.
All baseline questionnaires were completed by patients
on a laptop computer in the clinic or in the hospital and
included demographics, comorbid conditions, COPD
history (symptoms, duration of diagnosis, number of ex-
acerbations, and recent hospitalizations and ED visits),
and the PRO measures. The research assistant also
reviewed the clinical chart to record clinical variables
such as body mass index (BMI) and COPD medications.
If patients completed pulmonary function tests in-clinic
that same day, the values were obtained from the med-
ical chart and they were not asked to repeat the spirom-
etry for the study. The follow-up at 12 weeks (+ 30-day
window) was completed in-person in the clinic on the
laptop computer. If, during the course of follow-up, a
participant had a recurrent exacerbation, as defined pre-
viously, they were censored from analysis.
Measures
PROMIS measures
The primary goal of this study was to assess the respon-
siveness of PROMIS version 1.0 measures to changes as-
sociated with COPD exacerbation recovery. These
measures assessed anxiety, depression, anger [55], fatigue
[56], pain behavior [57], pain interference [58], physical
function [59], satisfaction with participation in discre-
tionary social activities [discretionary social activities],
satisfaction with participation in social roles [social
roles] [60], the 10-item Global Health short form [61]
(producing scores for physical health and mental health)
and dyspnea (Functional Assessment of Chronic Illness
Therapy (FACIT) dyspnea severity and functional limita-
tions measures). The FACIT dyspnea short forms (now
also included as PROMIS measures) consist of items
that assess dyspnea severity (10 items) and related func-
tional limitations (10 items) and were newly developed,
with this being the first longitudinal administration [62,
63].
PROMIS measures can be administered as fixed-
length short forms (SF) or dynamically by CAT. Ques-
tionnaires were administered using Assessment Cen-
terSM, a web-based data collection platform [64]. For
PROMIS CATs, the first item administered in a CAT is
usually one in the middle of the range of function or
symptom severity. After a person provides a response,
an estimated score is calculated. The CAT algorithm
then selects the best item in the item bank for refining
the estimated score. After a person provides a response,
the estimated score is recalculated. The CAT continues
to administer items until a specified level of measure-
ment precision is reached (standard error < 0.3 on theta
metric or 3.0 on a T-score metric) or a specified max-
imum number of items was administered (12). For this
study, Assessment Center administered the PROMIS
measures using CAT, followed by administration of any
remaining SF items that had not yet been administered
by CAT. These SF items were derived from the version
1.0 anger 8a, anxiety 7a, depression 8b, fatigue 7a, phys-
ical function 10a, pain interference 6b, pain behavior 7a,
discretionary social activities 7a, and social roles 7a short
forms.
PROMIS scores are estimated using item response the-
ory parameters and scored on a T-score metric, with 50
typically representing the mean and 10 the standard de-
viation in the U. S. general population (for most do-
mains). Exceptions to this include the PROMIS dyspnea
severity and functional limitations measures, for which
the mean and standard deviation (50/10) reflect the sam-
ple on which the measures were developed - people with
COPD. For all PROMIS measures, the direction of scor-
ing is guided by the domain name; higher scores indicate
more of the construct being measured. Thus, for the
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PROMIS domains of anger, anxiety, depression, fatigue,
dyspnea severity, dyspnea functional limitations, pain be-
havior and pain interference, higher scores indicate
worse health, and for domains of physical function, dis-
cretionary social activities, social roles, and Global
Health (physical health and mental health), higher scores
indicate better health.
Additional measures
We administered two PRO assessments commonly used
to assess COPD or related symptoms at baseline and
week 12. The St. George's Respiratory Questionnaire
(SGRQ) contains three domains (symptoms, activity, and
impacts) and a summary score on a 0–100 possible
range with 100 representing the worst HRQL [43]. The
Modified Medical Research Council (MMRC) dyspnea
scale is scored on a scale of 0 to 4 (0 = not troubled with
breathlessness except with strenuous exercise, to 4 = too
breathless to leave the house or breathless when dressing
or undressing) [65, 66]. We transformed the MMRC
score linearly to a 0–100 possible range (1 = 0; 2 = 25;
3 = 50; 4 = 75; 5 = 100) for some analyses.
Clinical measures
Two clinical assessments, FEV1 and the 6MWT, were
obtained from participants in a stable state (either base-
line or week 12). FEV1 was measured using a portable
spirometer administered by a research assistant trained
in spirometry. Study-related spirometry was not per-
formed if the patient had already undergone testing in-
clinic that same day. The 6MWT measured the distance
in meters that a participant was able to walk in a six-
minute time span [67].
Data analysis
Sample size considerations
Sample size estimates were based on an ability to detect
approximately medium effect sizes (ES) in PROMIS
scores between stable and acute COPD patients during
the 12-week period [68–70]. With intraclass correlation
of 0.5, a sample size of 81 in each group would enable
us to detect a medium between-group ES with 80%
power when using a two-sided alpha level of 0.05. Based
on our previous research experience and the literature,
we anticipated a 10% attrition rate over the 12-week
study period. Thus, we targeted a total sample size of
180 based on a 10% attrition rate to account for po-
tential study dropout and missing data for the
planned study. All power calculations are based on
the methods recommended in Cohen [71] and Krae-
mer and Thieman [72].
Data was summarized using descriptive statistics (e.g.,
means and standard deviation for continuous (and or-
dered) variables; frequency, mode and percentages for
categorical variables) for demographic variables and all
PRO and clinical measures. All item responses were ex-
amined using measures of central tendency (mean, me-
dian), spread (standard deviation, range), and response
category (frequencies).
Responsiveness is an aspect of construct validity [73]
and is estimated by evaluating the relationship between
changes in clinical or patient-reported “anchors” and
changes in the PRO scores over time; it can be evaluated
in intervention studies, clinical trials and observational
studies [74]. The COnsensus-based Standards for the se-
lection of health Measurement Instruments (COSMIN)
initiative [75] has proposed a definition of “responsive-
ness” as “The ability of an HR-PRO instrument to detect
change over time in the construct to be measured.” In
this paper, we examine responsiveness of the PROMIS
measures over 12 weeks in patients with COPD who
were recovering from an acute COPD exacerbation.
As detailed in Table 1, we hypothesized that some
PROMIS domains (physical function, fatigue, anxiety,
dyspnea severity, dyspnea functional limitations, discre-
tionary social activities and social roles) would be im-
paired during a COPD exacerbation, and recovery from
the exacerbation would be associated with improve-
ments in these domains. Associated with changes in
these physical and mental health domains, we also hy-
pothesized responsiveness during recovery in Global
Health (physical health and mental health). We hypothe-
sized no or small changes over the 12 week recovery
period for depression, anger, pain interference, and pain
behavior. We hypothesized little change between base-
line and 12 weeks on domains reported by participants
enrolled in a stable state, and any change observed
would be of a lesser magnitude than that observed in the
exacerbation group. Thus, we compared the slope of
changes in PROMIS and other PRO scores using mixed
models (details below). We used Cohen’s f2 as a measure
of local effect within a multivariate, mixed-effects regres-
sion model [71]. Cohen’s f2 convention is to classify
these ES as small (≥0.02), medium (≥0.15) or large
(≥0.35).
The mixed-effect model approach provides the flexibil-
ity of modeling not only the means of the data (as in the
standard linear model), but also individual patients’ vari-
ation over time. Mixed models take into account the fact
that measurements taken close in time are more highly
correlated than measurements taken far apart in time.
With mixed effect model approach, the slope of change
for fixed effect (e.g., between baseline and 12-weeks
later) is equivalent to the average group change. Other
advantages of using mixed models include its handling
of unbalanced research designs and missing data. In
model fitting, the mixed model uses all available data
from each subject rather than only including data from
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the subjects who have complete data at all of the time
points. While we attempted to over-sample to compen-
sate for the foreseeable loss of subjects due to dropout,
the use of mixed models minimizes the impact of data
missing throughout the course of the study. We hypoth-
esized that there would be significant improvement
(positive slope) in most PROMIS and clinical measures
in COPD patients during recovery to a stable period. For
each PROMIS and clinical outcome measure, the mixed
model included group (fixed effect; i.e., stable and ex-
acerbation), time (fixed effect; i.e., baseline and 12
weeks), and group by time interaction. We anticipated
there would be significant group by time interaction ef-
fects in the PRO measures hypothesized to show large
magnitude change (i.e., physical function, fatigue, anx-
iety, dyspnea severity, dyspnea functional limitations,
discretionary social activities, social roles, Global phys-
ical health and Global mental health), illustrating a dif-
ferent slope of change between the stable and
exacerbation groups across the 12-week study period for
these domains.
Product-moment correlations between clinical mea-
sures (6MWT and FEV1) and PROMIS and SGRQ
scores were estimated at baseline for stable patients and
for patients enrolled in an exacerbated state, when the
patients were deemed stable (i.e., 12 weeks after the
baseline visit).
Results
Across four sites, 770 individuals were screened. Of
those, 288 were ineligible (e.g., heart failure exacerba-
tion, smoking status, altered mental status, etc.), 212 re-
fused participation, 11 consented but withdrew before
completing an assessment, and 74 were not enrolled for
various and unknown reasons. One hundred individuals
with COPD were enrolled in a stable state and 85 were
enrolled in an exacerbated state. Of the stable subjects,
90 (90%) completed the study (3 withdrew due to health,
2 died, 3 lost to follow up, 2 withdrew for unknown rea-
sons) and 11 were censored due to exacerbations. Of the
85 in the exacerbation group, 61 (72%) completed the
study (2 withdrew due to health, 2 died, 11 lost to
follow-up, 9 withdrew for unknown reasons), and 15 had
subsequent exacerbations. Thus, at week 12 follow-up,
there were 79 (79%) individuals remaining in the stable
group and 46 (54%) in the exacerbation group.
We conducted post-hoc analyses to examine whether
drop-out differed by group (exacerbation vs stable). Re-
sults of the binary logistic regression indicated that the
exacerbation group experienced a higher rate of dropout
than the stable group (χ2(1) = 12.5, p = .0004). We exam-
ined whether age, gender, education, physical function
and fatigue were associated with dropout and found that
only physical function approached significance
(p = .0512). When we added physical function in the
model, the drop-out rate difference between the groups
remained significant (χ2(1) = 8.45, p = .0037). There were
no significant group by covariate interactions.
Baseline demographic and clinical characteristics of
the enrolled subjects are presented in Table 2. Those
enrolled in stable and exacerbation states did not
differ on any demographic characteristic other than
age, with the exacerbation group patients being
younger. Exacerbation group participants also re-
ported worse COPD and health at baseline. More
patients enrolled in an exacerbation state reported
having a COPD diagnosis for less than a year
(p = .03), having more exacerbations in the past 12
months (80%, p < .0001), more COPD-related hospi-
talizations in the past 12 months (72%, p < .0001) and
Table 1 PROMIS Measures and Hypothesized Responsiveness in COPD, with Results
PROMIS Measure Hypothesized Responsiveness Hypothesized Magnitude of Change Results (responsive/magnitude)
Physical Function Yes Large No/no effect
Pain Interference No Small No/no effect
Pain Behavior No Small No/no effect
Fatigue Yes Large Yes/small
Anxiety Yes Medium Yes/small
Depression No Small Yes/trivial
Anger No Small No/no effect
Discretionary Social Activities Yes Large No/trivial
Social Roles Yes Large Yes/small
Dyspnea - Severity Yes Large No/trivial
Dyspnea - Functional Limitations Yes Large No/trivial
Global Health - Physical Yes Large Yes/no effect
Global Health - Mental Yes Medium No/no effect
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Table 2 Baseline Demographic and Clinical Characteristics of Enrolled Patients
Characteristic Stable (n = 100) Exacerbation (n = 85) p-value
mean (sd) range mean (sd) range < 0.01
Age 64.6 (9.3) 60.5 (10.2)
Range: 43–85 Range: 41–88
BMI 31.10 (8.5) 32.10 (11.1) 0.51
Range: 18–65 Range: 16–79
Smoking pack year history 46.68 (27.3) 48.99 (34.5) 0.62
Range: 10–156 Range: 10–180
n (%) n (%) p-value
Age Category < 0.01
40–49 years 2 (2) 8 (9)
50–59 years 28 (28) 37 (44)
60–69 years 37 (37) 25 (29)
70+ years 33 (33) 15 (18)
Gender (Female) 43 (43) 43 (51) 0.30
Race (White) 75 (75) 60 (73) 0.78
Percent predicted FEV1 0.41
> = 80 4 (5) 2 (3)
50–79 35 (42) 27 (39)
30–49 33 (39) 23 (33)
< 30 12 (14) 17 (25)
6 min walk (> 300m) 46 (55) 17 (43) 0.20
Length of COPD diagnosis 0.03
< 1 yr 4 (4) 14 (17)
1–3 yrs 23 (23) 20 (24)
3–5 yrs 15 (15) 14 (17)
> 5 yrs 56 (57) 36 (43)
Exacerbations last 12 months < 0.0001
0 67 (68) 6 (7)
1 17 (17) 24 (28)
2 to 5 13 (13) 46 (54)
> 6 2 (2) 9 (11)
COPD hospitalizations last 12 months < 0.0001
0 84 (87) 13 (15)
1 9 (9) 39 (46)
2 to 5 4 (4) 30 (36)
> 6 0 (0) 2 (2)
COPD ED visits last 12 months < 0.0001
0 81 (83) 35 (41)
1 9 (9) 23 (27)
2 to 5 7 (7) 25 (29)
> 6 1 (1) 2 (2)
COPD medicationsa
Antibiotics 1 (1) 20 (24) < 0.0001
Beta agonists 94 (96) 80 (96) 0.87
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more COPD-related ED visits in the past 12 months
(50%, p < .0001).
The PRO scores for the baseline and 12-week follow-
up by baseline enrollment status as well as the respon-
siveness in PRO measures over 12 weeks, as evaluated by
the difference between stable and exacerbation group
differences over 12 weeks is summarized in Table 1 and
detailed in Table 3. Significant differences were found in
anxiety SF/CAT (p = .001/p < .01), fatigue (p < .0001/
p < .0001), social roles (p < .001/p < .05) and depression
(p < .05, SF only), with the exacerbation group reporting
greater change (improvement) than the stable group.
The magnitude of change (ES) for SF/CAT anxiety
(0.023/0.021), fatigue (0.036/0.047) and social roles
(0.035/0.024), which were hypothesized to be medium/
large/large, respectively, were all small. The ES for de-
pression (0.018) was trivial (less than the threshold for
small). Physical function, discretionary social activities,
and the Global-physical and Global-mental health scales,
all hypothesized to improve during recovery, did not sig-
nificantly change from baseline and had no to trivial ES.
Dyspnea severity and dyspnea functional limitations, also
hypothesized to improve during recovery, did not
change significantly but showed near-small ES (0.017,
0.015, respectively). All other PROMIS domains that
were hypothesized to have small to large ES demon-
strated trivial to no effect sizes. The SGRQ symptoms,
impacts and total scores (but not activities) also showed
significant change from baseline (all p < .0001) and all
(but activities) demonstrated small effect sizes.
As a reminder, the 6MWTs on patients enrolled in an
exacerbated state were performed at the 12-week follow-
up when patients had returned to stable state. Six-
minute walk scores were most highly correlated with
PROMIS CAT scores for physical function (r = 0.50,
p < .0001), fatigue (r = − 0.29, p < .01), depression (r = −
0.26, p < .01), discretionary social activities (r = 0.32,
p < .01) and social roles (r = 0.32, p < .01), with similar
correlations with SFs. Dyspnea severity/functional limi-
tations SFs (r = − 0.39/− 0.35, p < .01) and SGRQ Impacts
(r = − 0.22, p < .01) were also associated with six-minute
walk scores. Percent predicted FEV1 scores were signifi-
cantly correlated with PROMIS CATs for physical func-
tion (r = 0.32, p < .01), dyspnea severity (r = − 0.39,
p < .0001), functional limitations (r = − 0.25, p < .01) and
SGRQ Activities (r = − 0.25, p < .01).
Discussion
The HRQL of COPD patients during an exacerbation is
known to be significantly poorer than COPD patients in
a stable state [16, 41, 68, 76], and in our study, partici-
pants enrolled during an exacerbation reported worse
baseline health than those enrolled in stable status on
nearly all HRQL measures. Given the significant symp-
tom burden associated with exacerbations, these known
group differences were expected and provide some evi-
dence of construct validity of some PROMIS measures
for people with COPD.
Of the nine domains hypothesized to be responsive to
recovery from an exacerbation, only three demonstrated
statistically significant change using both SF and CAT,
and in none of the three was the hypothesized magni-
tude of change supported by the findings; all demon-
strated small effect sizes. We had hypothesized that pain
interference, pain behavior, depression and anger would
not change over the 12 weeks. Only the change in the
depression SF (not CAT) was statistically significant and
the ES was trivial (below the threshold for small). Finally,
we hypothesized that stable participants (exacerbation-
free at enrollment and throughout the study period)
would not demonstrate any change in PROs from base-
line to the 12-week follow-up. The changes in PRO
scores over 12 weeks in the stable group did reflect some
change, but the changes were uniformly of lesser magni-
tude than the changes in the exacerbation group. Given
the stability in their COPD during this time, such
changes may reflect variations in other life and non-
measured health events in these patients.
While some of the findings were unexpected, the most
curious and unexpected finding was the lack of change
in PROMIS physical function. Of note, the SGRQ did
not demonstrate change in the activity section of the
Table 2 Baseline Demographic and Clinical Characteristics of Enrolled Patients (Continued)
Characteristic Stable (n = 100) Exacerbation (n = 85) p-value
Inhaled steroids 59 (60) 52 (63) 0.74
Systemic steroids 3 (3) 40 (48) < 0.0001
Anticholinergenics 72 (74) 64 (77) 0.65
GOLD classification 0.43
GOLD 1 mild COPD 18 (19) 12 (17)
GOLD 2 moderate COPD 36 (39) 24 (33)
GOLD 3 severe COPD 25 (27) 28 (39)
GOLD 4 very severe COPD 14 (15) 8 (11)
aResponses are not mutually exclusive; participants could select more than one response
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instrument, which is most similar to the PROMIS phys-
ical function. One possibility is that physical function
does not change during recovery from an exacerbation,
but we reject this notion based on obvious clinical char-
acteristics of these patients. Declines in physical function
with the onset of exacerbations are well documented
Table 3 Changes in patient-reported outcomes (PRO) scores from mixed model1 (N = 185)
Measure Stable Group Exacerbation Group Difference
in
Differences
F-
statistic
P-value f2
Effect
Sizec
95% CI
Baseline
Meanb
12 week
Meanb
Baseline
Meanb
12 week
Meanb
PROMIS Short Forms
Anger 51.41 50.24 50.96 49.86 0.07 0.00 0.96 0.000 [−0.001,
0.001]
Anxiety 53.99 51.25 58.11 54.30 −1.06 3.18 < 0.001 0.023 [0.022, 0.024]
Depression 51.84 50.51 54.63 53.16 −0.13 2.38 < 0.05 0.018 [0.017, 0.019]
Fatigue 55.37 54.75 61.63 56.97 −4.04 4.89 <
0.0001
0.036 [0.035, 0.037]
Pain Behavior 53.63 52.12 55.54 53.63 −0.39 0.06 0.80 0.000 [−0.001,
0.001]
Pain Interference 57.29 55.66 59.43 57.26 −0.53 0.15 0.70 0.001 [0.000, 0.002]
Physical Function 36.97 37.29 34.50 35.35 0.54 1.41 0.17 0.011 [0.011, 0.011]
Discretionary Social
Activities
45.18 45.93 42.74 45.27 1.79 1.45 0.21 0.011 [0.010, 0.012]
Social Roles 43.26 42.51 39.38 42.27 3.64 4.73 < 0.001 0.035 [0.034, 0.036]
Dyspnea Severity 51.15 50.69 56.70 54.22 −2.01 2.68 0.10 0.017 [0.015, 0.019]
Functional Limitations 50.36 50.33 53.86 52.14 −1.69 1.77 0.18 0.015 [0.013, 0.017]
Global Physical 39.20 39.56 35.98 37.60 1.26 1.86 0.17 0.008 [0.007, 0.009]
Global Mental 43.75 43.07 45.02 44.71 0.37 0.12 0.73 0.001 [0.000, 0.002]
PROMIS CATs
Anger 52.11 50.86 51.46 50.21 0.01 0.00 0.99 0.000 [−0.001,
0.001]
Anxiety 54.99 52.13 59.64 55.42 −1.36 2.75 < 0.01 0.021 [0.021, 0.021]
Depression 51.98 50.32 55.27 53.50 −0.12 1.62 0.17 0.012 [0.011, 0.013]
Fatigue 56.80 54.53 63.24 57.08 −3.89 6.26 <
0.0001
0.047 [0.046, 0.048]
Pain Behavior 53.98 52.43 55.90 54.43 0.08 0.00 0.96 0.000 [−0.001,
0.001]
Pain Interference 57.53 55.51 60.72 58.18 −0.51 0.10 0.76 0.001 [0.000, 0.002]
Physical Function 37.11 37.34 35.26 35.78 0.29 0.98 0.46 0.007 [0.007, 0.007]
Discretionary Social
Activities
44.33 45.57 41.99 44.91 1.68 1.19 0.31 0.009 [0.008, 0.010]
Social Roles 42.89 42.61 39.54 42.31 3.05 3.03 0.02 0.024 [0.023, 0.025]
SGRQ
SGRQ Symptoms 57.24 58.30 71.74 58.36 −14.44 24.54 <
0.0001
0.133 [0.129, 0.137]
SGRQ Activities 68.61 67.09 77.35 72.26 −3.57 2.03 0.15 0.011 [0.009, 0.013]
SGRQ Impacts 40.66 40.15 53.25 43.18 −9.56 15.31 < 0.001 0.094 [0.090, 0.098]
SGRQ Total 51.84 51.30 63.66 54.50 −8.62 18.98 <
0.0001
0.118 [0.114, 0.122]
MMRC 41.28 37.85 53.04 48.95 −0.66 0.02 0.89 0.000 [−0.001,
0.001]
aResults in this table come from a mixed-effects model that included age, number of exacerbations in past year, group (fixed effect; i.e., stable or exacerbation),
time (fixed effect; i.e., baseline or 12 weeks) and group-by-time interaction; bleast square means; cCohen f2, ≥0.02 = small, ≥0.15 =medium, ≥0.35 large; CAT
Computer adaptive test, SGRQ St. George’s Respiratory Questionnaire, MMRC Modified Medical Research Council dyspnea scale
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[48, 77, 78]. Furthermore, physical function (as mea-
sured with PROMIS) has been shown to affect people
across the spectrum of disease severity, including mild
disease, whereas mental health was impaired only in pa-
tients with more severe disease [78]. Lung function does
not always return to pre-exacerbation levels following an
exacerbation, but the trajectory of recovery of physical
function/activity is less well established [79–81]. Some
reports have documented recovery to (or nearly to) base-
line levels [82]. One of the few longitudinal studies
evaluating “objectively” measured (accelerometer) phys-
ical activity for up to 6 months during COPD exacerba-
tions and periods of clinical stability found that physical
activity decreased significantly during exacerbations and
persisted for about 2 weeks after symptomatic recovery.
Others have reported a slow recovery trajectory or fail-
ure to return to baseline [5, 83], leading some to suggest
that recovery in health status after an exacerbation may
take longer than previously expected [48]. It is possible
that improvement in physical function following an ex-
acerbation takes longer than 12 weeks. In addition to the
literature that contradicts this [81, 84, 85], we censored
individuals with subsequent exacerbations, which is
likely to have eliminated those with an extended recov-
ery trajectory. Finally, these patients may be sedentary in
the absence of exacerbation and not regularly testing
their own physical function [86, 87].
An alternative explanation is that physical recovery oc-
curs, but the PROMIS physical function measures (and
SGRQ activity measure) did not detect it. This might
have occurred for several reasons. The severity of exac-
erbations experienced by our participants might not
have been of sufficient magnitude to be reflected in
physical function recovery; however, 38 of the partici-
pants enrolled during an exacerbated state were hospi-
talized for their exacerbation, suggesting severe
exacerbations. It is also possible that the sample size
limited the power to detect significant change. The
dropout in the exacerbation group was larger than antic-
ipated and resulted in a sample size at follow-up smaller
than the power analysis indicated was needed to detect
hypothesized change. However, some other domain
measures demonstrated significant change, so there ap-
peared to be adequate power for the other domains. An-
other explanation is the possibility that, for the physical
function items, patient responses during an exacerbation
did not reflect their true current (i.e., exacerbation) state.
Most PROMIS domains have a 7-day context (“In the
past 7 days …”), but the physical function items do not
have a specific time interval. It is possible that patients
were not reflecting on their exacerbation (and often hos-
pitalized) state, but rather they were considering their
physical capability prior to deterioration. Thus, the lack
of a context might represent an opportunity for
participants to variably interpret their “current” state of
health. The lack of context may work well in a state
without rapid changes (e.g., arthritis), but may not work
as well for conditions with acute periods of worsening
(e.g., COPD). Some support for this derives from ana-
lyses of other chronic conditions. For example, the PRO-
MIS physical function scores for stable patients and
those recovering from a COPD exacerbation in this
study (34–38) are not altogether dissimilar from physical
function scores from samples of patients with back pain
and chronic heart failure prior to receiving an interven-
tion (38 and 35, respectively) [36]. However, the back
pain and heart failure samples demonstrated notable im-
provements in physical function scores in response to
clinical interventions (all p ≤ 0.001) [36]. Investigators
hypothesized that, in contrast with the relatively stable
disability associated with back pain and heart failure,
acute worsening associated with COPD exacerbations
may lead patients to over-report their physical function
because they reference their usual state rather than
acutely ill state [36]. However, to our knowledge, there
is no evidence at present to support the possibility that
reframing the question (e.g., “Considering how you feel
right now…”) would produce different results, so this re-
mains a hypothesis for future research to evaluate.
Similarly, we did not demonstrate significant change
in the PROMIS dyspnea severity and functional limita-
tion measures. It’s reasonable to expect dyspnea severity
and functional limitations to improve during recovery
from a COPD exacerbation, as dyspnea is one of the pri-
mary symptoms associated with an exacerbation. How-
ever, these were newly developed measures and this was
the first longitudinal study in which they had been ad-
ministered. Items on both measures reference the same
set of activities, and individuals may not have had the
opportunity to perform some of these activities during
an exacerbation state, especially if hospitalized (e.g., pre-
paring meals, washing dishes). The MMRC dyspnea
scale score also did not improve during the recovery,
and it is similarly based on activity (e.g., walking, strenu-
ous exercise, etc.). Although the effect sizes reflecting
change in PROMIS dyspnea severity and functional limi-
tations approached the threshold for small magnitude
and did not reach statistical significance in this study,
prior cross-sectional studies have provided support for
the reliability and validity of these measures in COPD
[62, 63, 78] and other chronic lung diseases [88], sug-
gesting that the small sample size might have limited the
responsiveness observed here.
Our findings indicate that responsiveness to change
was demonstrated for three of the nine PROMIS do-
mains in which change was hypothesized. While there is
only limited support for responsiveness among the do-
mains tested, the score differences and the effect sizes
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reflecting the difference in differences between the two
groups reflected greater magnitude of change in the ex-
acerbation group. With the exception of depression, re-
sponsiveness to changes was similar for the PROMIS
dynamic CATs and corresponding static SFs, suggesting
there is no advantage of one administration option over
the other, with equivalent precision and responsiveness
to clinicians and researchers. CAT administration offers
the advantage of minimal participant burden without
sacrificing measurement precision, but requires a com-
puter for administration. Short forms can be adminis-
tered via paper and pencil and do not require a
computer for administration. Both were developed with
rigorous qualitative and quantitative methodology and
offer the advantages of comparability across conditions,
reliability, validity, and precision.
SGRQ total, symptoms, and impacts scores signifi-
cantly discriminated longitudinal change between the
stable and exacerbation groups, indicating the health sta-
tus of these two groups were different, consistent with
the intent of the study design. Three PROMIS measures
fatigue, anxiety and social roles, also demonstrated dif-
ferential longitudinal change between the two groups.
We note also that the magnitude of effect sizes for the
SGRQ symptoms and impacts subscales scores and total
score were in the small range, albeit larger than that of
the PROMIS measures. This is not unexpected, because
one of the putative benefits of disease-specific compared
to generic measures is their sensitivity to the disease it-
self. The SGRQ mean score for symptoms, impacts and
total score (but not activities) for the exacerbation group
also exceeded the minimal clinically important difference
threshold estimates reported in the literature (4–7), in-
cluding the higher threshold (7+) for patients with se-
vere disease [89–93].
There are several limitations to this study worth not-
ing. Both groups experienced drop-out, but this was
most prominent in the exacerbation group, which re-
duced the available sample size and precision of our esti-
mates of change. However, we were still able to
demonstrate responsiveness, i.e., change over the course
of recovery from an exacerbation, in some measures that
were hypothesized to reflect such a change. Neverthe-
less, the high dropout rate likely limited our power to
detect the hypothesized effect size. The demographic
and clinical characteristics of patients lost to follow-up
were not significantly different from those of patients
that completed the study. Fatigue and physical function
(as measured by both PROMIS SF and CAT) were asso-
ciated with drop out, however, with those who dropped
out from the exacerbation group demonstrating the
highest levels of fatigue and lowest levels of physical
function. The findings still showed strong evidence of
responsiveness in the fatigue measures in the
exacerbation group, but it is unclear if or how this might
have impacted responsiveness of the physical function
measures. We recruited participants across four distinct
clinical sites, but our sample size precluded our ability
to analyze site differences. However, a rigorous three-
day face-to-face training was held for all study staff be-
fore the study was launched to standardize implementa-
tion of the study protocol and ensure consistent
recruitment, enrollment and assessment procedures.
Conclusion
This longitudinal study provides some initial support for
the responsiveness of the PROMIS fatigue, anxiety and
social roles domains relevant to COPD. As responsive-
ness is one element of a measure’s validity [73], this
study provides some preliminary evidence of validity of
some of the PROMIS measures as well. Further longitu-
dinal studies with larger sample sizes are required to
evaluate additional aspects of reliability and validity of
the PROMIS measures and their performance in the
COPD population. Additional evaluation of selected do-
mains, especially the PROMIS physical function domain,
is warranted, given the lack of responsiveness in this
study.
Because PROMIS measures are generic, they can be
used to assess the relative health status of respondents
across diseases or functional characteristics. The mul-
tiple options for PROMIS administration (various short
form lengths and CAT), allow for a customizable and ef-
ficient solution for measuring health outcomes import-
ant to patients. PROMIS is a useful tool for tracking
select domains of HRQL in patients with COPD for re-
search and possibly for clinical care.
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